Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 20/20 | 0.82 |
| ▸ | EGLN3 | Q9H6Z9 | 7/20 | 0.82 |
| ▸ | VEGFA | P15692 | 7/20 | 0.82 |
| ▸ | FLT1 | P17948 | 7/20 | 0.82 |
| ▸ | TET3 | O43151 | 1/20 | 0.82 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.82 |
| ▸ | ASPH | Q12797 | 1/20 | 0.82 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.82 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.82 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.82 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.82 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.82 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vadadustat SCHEMBL29357486 | 0.90 | EGLN1 (1.00) | EGLN1EGLN3VEGFAFLT1TET3 | |
| Vadadustat SCHEMBL1920738 | 0.90 | EGLN1 (1.00) | EGLN1EGLN3VEGFAFLT1TET3 | |
| Vadadustat SCHEMBL29405970 | 0.90 | EGLN1 (1.00) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL30239851 | 0.89 | EGLN1 (0.80) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL15164149 | 0.89 | EGLN1 (0.80) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL16728915 | 0.89 | EGLN1 (0.80) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL1921390 | 0.89 | EGLN1 (0.80) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL20711169 | 0.89 | EGLN1 (0.76) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL14308517 | 0.88 | EGLN1 (0.83) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL1921042 | 0.87 | EGLN1 (1.00) | EGLN1EGLN3VEGFAFLT1TET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190290624-A1 | SOLID FORMS OF {[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO}ACETIC ACID, COMPOSITIONS, AND USES THEREOF | KREOS CAPITAL VII (UK) LIMITED (GB) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190290624-A1 | SOLID FORMS OF {[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO}ACETIC ACID, COMPOSITIONS, AND USES THEREOF | VHL, OTC, GLS2 | EGLN1 1145/4885EGLN3 142/4885VEGFA 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.